)
)
)
Duo Oncology
Duo Oncology was founded by oncologists dedicated to improving patients’ lives. Our mission is to build a stronger, safer foundation for cancer medicine by replacing toxic chemotherapy with responsive therapeutics.
Our patented prodrug chemistry protects healthy tissues and organs while delivering potent chemotherapies and precision small molecules deep into solid tumors. Our lead product, DUO-207, a replacement for paclitaxel and gemcitabine, has demonstrated superiority to standard therapies in GLP toxicology studies.
In Q1 2026, DUO-207 will begin an adaptive clinical trial enrolling patients with pancreatic, lung, or breast cancer. Duo’s open Seed+ and upcoming Series A rounds will fund treatment for up to 80 patients and generate the safety and overall response rate data that are key value drivers for acquisition.
Address
PittsburghUnited States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)